PSMA-PET Imaging Before & After ADT in Advanced SDC Patients

Status Recruiting

Clinical Trial Summary

Explorative study, which evaluates the effect of androgen deprivation therapy (ADT) on the PSMA ligand uptake on 68Ga-PSMA-PET/CT in salivary duct carcinoma patients.

Clinical Trial Description

Rationale: Prostate specific membrane antigen (PSMA) is a transmembrane protein, which is expressed on prostate cancers cells and other malignancies. Recently, several ligands have been developed that target PSMA. Linked to Gallium-68, this enables diagnostic 68Ga-PSMA-PET/CT scans. Linked to Lutetium-177 enables therapeutic 177Lu-PSMA Radioligand therapy. Most research on the diagnostic and therapeutic possibilities of PSMA has been conducted in patients with advanced prostate cancer. This research group investigates whether these findings also apply to salivary gland cancer (SGC), a rare cancer. Previously the investigators conducted a phase II 68Ga-PSMA imaging study (NCT03319641), to evaluate PSMA ligand uptake in locally advanced, recurrent and metastatic ACC and SDC (two subtypes of SGC). A relevant PSMA-ligand uptake was observed in 93% of ACC patients and 40% of SDC patients. However, since 60% of SDC patients showed low ligand uptake, these patients are not suitable for PSMA radioligand therapy. For advanced SDC, androgen deprivation therapy is often given as first-line treatment, because the majority of SDCs are androgen receptor positive. In prostate cancer, androgen deprivation therapy (ADT) can increase PSMA-ligand uptake. Therefore the aim is to investigate if ADT can increase the uptake of 68Ga-PSMA in patients with R/M SDC, as has previously been demonstrated in prostate cancer. Objective: The primary objective is to investigate if ADT can increase the uptake of 68Ga-PSMA in patients with R/M SDC. Study design: Interventional clinical trial, an explorative study. Study population: Patients with locally advanced, recurrent or metastatic (R/M) SDC AR+ and who will start ADT as standard of care. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04214353
Study type	Interventional
Source	Radboud University Medical Center
Contact
Status	Recruiting
Phase	N/A
Start date	January 14, 2020
Completion date	September 2023

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03729297` - Cabozantinib in Advanced Salivary Gland Cancer Patients	Phase 2
Active, not recruiting	`NCT01969578` - Androgen Deprivation Therapy in Advanced Salivary Gland Cancer	Phase 2
Completed	`NCT01703455` - Activity of Sorafenib in Salivary Gland Cancer	Phase 2
Recruiting	`NCT04140526` - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Phase 1/Phase 2
Active, not recruiting	`NCT05010629` - 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma	Phase 2
Suspended	`NCT03781986` - APG-115 in Salivary Gland Cancer Trial	Phase 1/Phase 2
Completed	`NCT03319641` - PSMA-PET Imaging for Advanced ACC/SDC	N/A
Recruiting	`NCT02012699` - Integrated Cancer Repository for Cancer Research
Recruiting	`NCT04028479` - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting	`NCT05483374` - The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
Completed	`NCT04291300` - Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients	Phase 2
Active, not recruiting	`NCT03172624` - Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer	Phase 2
Completed	`NCT00509002` - Iressa Study in Patients With Salivary Gland Cancer	Phase 2
Active, not recruiting	`NCT05008237` - Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study	Phase 2
Recruiting	`NCT03360890` - Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors	Phase 2
Not yet recruiting	`NCT06091878` - Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers
Not yet recruiting	`NCT05898373` - Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC	Phase 1/Phase 2
Active, not recruiting	`NCT02069730` - A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes	N/A
Recruiting	`NCT04209660` - Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers	Phase 2
Completed	`NCT01344356` - Stereotactic Body Radiotherapy for Head and Neck Tumors	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

PSMA-PET Imaging Before and After ADT in Advanced SDC Patients — ADT-SCAN

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms